Cognitive alterations in patients with non-affective psychotic disorder and their unaffected siblings and parents

Acta Psychiatrica Scandinavica

Volumn 125, Issue 1, 2012, Pages 66-76

  Meijer, J ^a   Simons, C J P ^b,c   Quee, P J ^d   Verweij, K ^e   Kahn, René S ^f   Cahn, Wiepke ^f   Linszen, Don H ^g   de Haan, Lieuwe ^g   van Os, Jim ^b,h   Krabbendam, Lydia ^b   Myin Germeys, Inez ^b   Wiersma, Durk ^d   Bruggeman, Richard ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GGzE Foundation for Mental Health Care Eindhoven en de Kempen   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Endophenotypes; Neuropsychology; Parents; Schizophrenia; Siblings

Indexed keywords

CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ALERTNESS; ARTICLE; ATTENTION; CHILD; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; KNOWLEDGE; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY; PARENT; PHENOTYPE; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOSIS; SCHOOL CHILD; SIBLING; SOCIAL COGNITION; THINKING; WORKING MEMORY;

EID: 83555174361     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2011.01777.x     Document Type: Article

References (54)

1. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004;72:41-51.
2. Broome MR, Matthiasson P, Fusar-Poli P et al. Neural correlates of movement generation in the 'at-risk mental state'. Acta Psychiatr Scand 2010;122:295-301.
3. Pukrop R, Klosterkötter J. Neurocognitive indicators of clinical high-risk states for psychosis: a critical review of the evidence. Neurotox Res 2010;18:272-286.
4. Keshavan MS, Kulkarni SR, Bhojraj T et al. Premorbid cognitive deficits in young relatives of schizophrenia patients. Front Hum Neurosci 2010;5:12.
5. Sitskoorn MM, Aleman A, Ebisch SJH, Appels MCM, Kahn RS. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res 2004;71:285-295.
6. Snitz B, Macdonald A, Carter C. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 2006;32:179-194.
7. Jabben N, Van Os J, Janssen I, Versmissen D, Krabbendam L. Cognitive alterations in groups at risk for psychosis: neutral markers of genetic risk or indicators of social disability? Acta Psychiatr Scand 2007;116:253-262.
8. Kéri S, Janka Z. Critical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia. Acta Psychiatr Scand 2004;110:83-91.
9. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000;53:207-216.
10. Palmer B, Dawes S, Heaton R. What do we know about neuropsychological aspects of Schizophrenia? Neuropsychol Rev 2009;19:365-384.
11. Genetic Risk and Outcome in Psychosis (GROUP) Investigators. Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Arch Gen Psychiatry 2010;68:138-147.
12. Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-449.
13. Van Os J, Burns T, Cavallaro R et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006;113:91-95.
14. Brand N, Jolles J. Learning and retrieval rate of words presented auditorily and visually. J Gen Psychol 1985;112:201-210.
15. Nuechterlein KHR, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenics disorders. Schizophr Bull 1984;10:160-203.
16. Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull 1992;28:353-366.
17. Nolan KA, Bilder RM, Lachman HM, Volavka J. Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. Am J Psychiatry 2004;161:359-361.
18. Meiran N, Levine J, Meiran N, Henik A. Task set switching in schizophrenia. Neuropsychology 2000;14:471-482.
19. Wechsler D. WAIS-III: Wechsler adult intelligence scale, 3rd edn. Administration and Scoring Manual. San Antonio, TX, USA: Psychological Corporation, 1997.
20. Egeland J, Bosnes O, Johansen H. Factor structure of the Norwegian version of the WAIS-III in a clinical sample. Assessment 2009;16:292-300.
21. Van'T Wout M, Aleman A, Kessels RPC, Larøi F, Kahn RS. Emotional processing in a non-clinical psychosis-prone sample. Schizophr Res 2004;68:271-281.
22. Benton AL, Sivan AB, Hamsher K, Varney NR, Spreen O. Benton's test of facial recognition. New York: Oxford University Press, 1983.
23. Versmissen D, Janssen I, Myin-Germeys I et al. Evidence for a relationship between mentalising deficits and paranoia over the psychosis continuum. Schizophr Res 2008;99:103-110.
24. Keefe RSE, Harvey PD, Goldberg TE et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res 2008;102:108-115.
25. Glass GV. Primary, secondary, and meta-analysis of research. Educ Research 1976;5:3-8.
26. Greenwood TA, Braff DL, Light GA et al. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry 2007;64:1242-1250.
27. Heinrichs RW, Awad AG. Neurocognitive subtypes of chronic schizophrenia. Schizophr Res 1993;9:49-58.
28. Keefe RSE, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 2007;33:912-920.
29. Palmer BW, Heaton RK, Paulsen JS et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 1997;11:437-446.
30. Kremen WS, Seidman LJ, Faraone SV, Toomey R, Tsuang MT. The paradox of normal neuropsychological function in schizophrenia. J Abnorm Psychol 2000;109:743-752.
31. Yücel M, Bora E, Lubman DI et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2010; 10.1093/schbul/sbq079.
32. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 2007;64:532-542.
33. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-445.
34. Morice R, Delahunty A. Frontal/executive impairments in schizophrenia. Schizophr Bull 1996;22:125-137.
35. Sprong M, Schothorst P, Vos E, Hox J, Van Engeland H. Theory of mind in schizophrenia: meta-analysis. Br J Psychiatry 2007;191:5-13.
36. Bediou B, Franck N, Saoud M et al. Effects of emotion and identity on facial affect processing in schizophrenia. Psychiatry Res 2005;133:149-157.
37. Savla GN, Twamley EW, Delis DC, Roesch SC, Jeste DV, Palmer BW. Dimensions of executive functioning in schizophrenia and their relationship with processing speed. Schizophr Bull 2010; 10.1093/schbul/sbq149.
38. Gur RE, Nimgaonkar VL, Almasy L et al. Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophrenia. Am J Psychiatry 2007;164:813-819.
39. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994;20:31-46.
40. Ceaser AE, Goldberg TE, Egan MF, Mcmahon RP, Weinberger DR, Gold JM. Set-shifting ability and schizophrenia: a marker of clinical illness or an intermediate phenotype? Biol Psychiatry 2008;64:782-788.
41. Appels MCM, Sitskoorn MM, De Boo M et al. Neurological signs in parents of schizophrenic patients. NeuroReport 2002;13:575-579.
42. Anselmetti S, Bechi M, Bosia M et al. 'Theory' of mind impairment in patients affected by schizophrenia and in their parents. Schizophr Res 2009;115:278-285.
43. Bora E, Yücel M, Pantelis C. Theory of mind impairment: a distinct trait-marker for schizophrenia spectrum disorders and bipolar disorder? Acta Psychiatr Scand 2009;120:253-264.
44. Kelemen O, Kéri S, Must A, Benedek G, Janka Z. No evidence for impaired 'theory of mind' in unaffected first-degree relatives of schizophrenia patients. Acta Psychiatr Scand 2004;110:146-149.
45. Sergi MJ, Rassovsky Y, Widmark C et al. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res 2007;90:316-324.
46. Van Hooren S, Versmissen D, Janssen I et al. Social cognition and neurocognition as independent domains in psychosis. Schizophr Res 2008;103:257-265.
47. Addington J, Saeedi H, Addington D. Influence of social perception and social knowledge on cognitive and social functioning in early psychosis. Br J Psychiatry 2006;189:373-378.
48. Vauth R, Rüsch N, Wirtz M, Corrigan PW. Does social cognition influence the relation between neurocognitive deficits and vocational functioning in schizophrenia? Psychiatry Res 2004;128:155-165.
49. Egan MF, Goldberg TE, Gscheidle T et al. Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry 2001;50:98-107.
50. Welham J, Scott J, Williams GM et al. The antecedents of non-affective psychosis in a birth-cohort, with a focus on measures related to cognitive ability, attentional dysfunction and speech problems. Acta Psychiatr Scand 2010;121:273-279.
51. Kremen WS, Seidman LJ, Faraone SV, Pepple JR, Lyons MJ, Tsuang MT. The '3 Rs' and neuropsychological function in schizophrenia: a test of the matching fallacy in biological relatives. Psychiatry Res 1995;56:135-143.
52. Miller GM, Chapman JP. Misunderstanding analysis of covariance. J Abnorm Psychol 2001;110:40-48.
53. Keefe RSE, Bilder RM, Harvey PD et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006;31:2033-2046.
54. Blyler CR, Gold JM, Iannone VN, Buchanan RW. Short form of the WAIS-III for use with patients with schizophrenia. Schizophr Res 2000;46:209-215.